8-K filing — Inhibrx Biosciences, Inc. (INBX)
Filed: 2026-09-08 AccNo: 0002007919-26-000047 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Inhibrx Biosciences shares are trading lower. The company announced primary endpoint results from the Phase 2 HexAgon study of INBRX-106, an OX40 agonist, combined with pembrolizumab versus pembrolizumab alone in PD-L1 positive head and neck squamous cell carcinoma.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.
Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times